Poster Presentations Overview:Title: Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-IIPresenter: Geoffrey Liu, M.Sc., M.D., Professor, Princess Margaret Cancer Centre, Temerty School of Medicine, University of TorontoSession Title: Phase II Clinical TrialsDate: Tuesday, April 21, 2026Session Time: 2:00-5:00 p.m. PSTPoster Board Number: 9Abstract Number: #CT244 Nuvation Bio to Present Pivotal IBTROZI® (Ta ...